The first clinical trial will evaluate whether early access to a patient’s genomic data can benefit treatment of high blood pressure, hypertension and chronic kidney disease. A second trial will test whether patients with acute post-surgical pain, chronic pain and depression experience better outcomes if physicians take pharmacogenomics into account when prescribing opioids and antidepressants.
The NIH will invest up to $42 million over the course of five years into the trials. The initiative comprises the second phase of the Implementing Genomics in Practice (IGNITE) Network, which is funded by the NIH’s National Human Genome Research Institute and was initially launched to incorporate genomic information into electronic health records.
More articles about health IT:
UnityPoint Health launches $100M venture fund to invest in digital health
Williamson Memorial Hospital selects Meditech EHR: 3 notes
Ice Bucket Challenge led to largest ALS genomic sequencing study in US
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.